June 29, 2023 Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
Sept 28, 2022 Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis
Sept 8, 2022 Alumis Appoints Jörn Drappa M.D., Ph.D., as Chief Medical Officer and Roman G. Rubio, M.D., as Senior Vice President, Clinical Development and Translational Medicine
Aug 3, 2022 Alumis Appoints Sapna Srivastava, Ph.D., to its Board of Directors
Apr 6, 2022 Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as
Jan 6, 2022 Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases
Sept 23, 2021 Esker Therapeutics Announces Management and Research Team Additions to Accelerate Advancement of Precision Immunology Therapies
Aug 19, 2021 Esker Therapeutics Appoints Jeff Douglas as Vice President of Clinical Operations
July 21, 2021 Esker Therapeutics Appoints New Team Members and Board Director
May 5, 2021 Esker Therapeutics Launches to Transform the Treatment of Autoimmune Diseases
